These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19825951)

  • 1. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.
    Herbertson RA; Tebbutt NC; Lee FT; MacFarlane DJ; Chappell B; Micallef N; Lee ST; Saunder T; Hopkins W; Smyth FE; Wyld DK; Bellen J; Sonnichsen DS; Brechbiel MW; Murone C; Scott AM
    Clin Cancer Res; 2009 Nov; 15(21):6709-15. PubMed ID: 19825951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
    Saleh MN; Sugarman S; Murray J; Ostroff JB; Healey D; Jones D; Daniel CR; LeBherz D; Brewer H; Onetto N; LoBuglio AF
    J Clin Oncol; 2000 Jun; 18(11):2282-92. PubMed ID: 10829049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
    Krug LM; Milton DT; Jungbluth AA; Chen LC; Quaia E; Pandit-Taskar N; Nagel A; Jones J; Kris MG; Finn R; Smith-Jones P; Scott AM; Old L; Divgi C
    J Thorac Oncol; 2007 Oct; 2(10):947-52. PubMed ID: 17909358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.
    Kelly MP; Lee FT; Tahtis K; Power BE; Smyth FE; Brechbiel MW; Hudson PJ; Scott AM
    Cancer Biother Radiopharm; 2008 Aug; 23(4):411-23. PubMed ID: 18771345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by (111)Indium-labeled humanized monoclonal antibody 3S193.
    Quaia E; Krug LM; Pandit-Taskar N; Nagel A; Reuter VE; Humm J; Divgi C
    Eur J Radiol; 2008 Aug; 67(2):292-299. PubMed ID: 17714905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
    Smaletz O; Diz MD; do Carmo CC; Sabbaga J; Cunha-Junior GF; Azevedo SJ; Maluf FC; Barrios CH; Costa RL; Fontana AG; Madrigal V; Wainstein AJ; Yeda FP; Alves VA; Moro AM; Blasbalg R; Scott AM; Hoffman EW
    Gynecol Oncol; 2015 Aug; 138(2):272-7. PubMed ID: 26026738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.
    Scott AM; Tebbutt N; Lee FT; Cavicchiolo T; Liu Z; Gill S; Poon AM; Hopkins W; Smyth FE; Murone C; MacGregor D; Papenfuss AT; Chappell B; Saunder TH; Brechbiel MW; Davis ID; Murphy R; Chong G; Hoffman EW; Old LJ
    Clin Cancer Res; 2007 Jun; 13(11):3286-92. PubMed ID: 17545534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
    Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
    Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
    Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
    J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
    Ross HJ; Hart LL; Swanson PM; Rarick MU; Figlin RA; Jacobs AD; McCune DE; Rosenberg AH; Baron AD; Grove LE; Thorn MD; Miller DM; Drachman JG; Rudin CM
    Lung Cancer; 2006 Oct; 54(1):69-77. PubMed ID: 16934909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
    Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
    Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.
    Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
    Cancer Res; 2000 Sep; 60(17):4804-11. PubMed ID: 10987290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy.
    Testa L; Mano M; Arai RJ; Bonadio RC; Serrano SV; Zorzetto MMC; Crocamo S; Smaletz O; Freitas-Junior R; Hoff PM
    Clinics (Sao Paulo); 2021; 76():e3146. PubMed ID: 34644735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.
    Ma Y; Kowolik CM; Swiderski PM; Kortylewski M; Yu H; Horne DA; Jove R; Caballero OL; Simpson AJ; Lee FT; Pillay V; Scott AM
    ACS Chem Biol; 2011 Sep; 6(9):962-70. PubMed ID: 21766840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
    Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
    Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels.
    Lövqvist A; Humm JL; Sheikh A; Finn RD; Koziorowski J; Ruan S; Pentlow KS; Jungbluth A; Welt S; Lee FT; Brechbiel MW; Larson SM
    J Nucl Med; 2001 Aug; 42(8):1281-7. PubMed ID: 11483692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
    Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
    Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.